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Abstract 
Proteoglycans are considered to facilitate lipid accumulation i  the arterial wall, as part of the injury and repair process in 
atherogenesis. The present study determined (1) characteristics of arterial tissue chondroitin sulfate proteoglycan (CS-PG) monomers of 
versican type that vary in binding affinity to low-density lipoproteins (LDL), and (2) the ability of these variants to modulate LDL 
metabolism by macrophages. A large CS-PG devoid of dermatan sulfate (DS) was isolated and purified from bovine aorta intima-media 
under dissociative conditions. The proteoglycan was further subfractionated by LDL affinity chromatography into CS-PGI and CS-PGII 
variants, the former eluting at 0.1 M NaC1 and the latter at 1.0 M NaCI. The core protein of both variants had a similar molecular mass 
(1.7. 103). However, CS-PGII contained more glycosaminoglycan (GAG) chains (30 vs. 25) with higher average molecular mass 
(4.2 - 104 vs. 3.8 • 104) than CS-PGI. Furthermore, CS-PGII contained a relatively higher proportion of CS6-sulfate to CS4-sulfate (65:35 
vs. 52:48). Sulfate-to-hexosamine molar ratio of GAG measured approximately 1 in both variants. In terms of metabolism by 
macrophages, when compared to complex of LDL and CS-PGI, complex of LDL and CS-PGII produced consistent increase in 
degradation (10.3-fold vs. 8.4-fold over native LDL) and cell association (16.3-fold vs, 10.2-fold over native LDL) of the ligand, and 
stimulation of cholesteryl ester synthesis (8.4-fold vs. 6.4-fold over native LDL). CS-PGII was as potent as native CS/DS-PG aggregate, 
which is a complex made of proteoglycan monomers, hyaluronate, and link protein(s), in stimulating the above activities in macrophages. 
Thus, variations in LDL-binding affinity of CS-PG can potentially modulate the lipid accumulation i atherogenesis. 
Keywords: Arterial tissue chondroitin sulfate proteoglycan variant; LDL binding affinity; LDL metabolism; (Macrophage) 
1. Introduction 
Proteoglycans have been implicated in the accumulation 
of extracellular and intracellular lipids in the arterial wall, 
as part of the injury and repair process during atherogene- 
sis [1,2]. This is based on previous findings: (1) arterial 
proteoglycans interact selectively with plasma apolipo- 
protein B-containing lipoproteins, especially low-density 
lipoproteins (LDL) [3-7]; (2) proteoglycans increase with 
development of atherosclerotic lesions and lipoprotein de- 
position [8,9]; (3) LDL-proteoglycan complex occurs in 
atherosclerotic lesions [ 10-12]; and (4) LDL-proteoglycan 
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complex stimulates cholesteryl ester accumulation in 
macrophages leading to formation of foam cells, akin to 
those found in atherosclerotic lesions [13-16]. 
Proteoglycans occur as polydisperse macromolecules in 
the vasculature due to variability in size, charge density, 
and chemical characteristics of constituent glycosamino- 
glycan (GAG) chains. The nature of GAG chains in pro- 
teoglycans determines their ability to bind LDL [17-20]. 
Therefore, certain variant or subfraction of a proteoglycan 
can bind LDL more avidly than others. Recently, we 
demonstrated that a variant of isomeric chondroitin sulfate 
proteoglycan (CS/DS-PG) from aorta binds LDL with 
affinity similar to that of heparin, heretofore considered to 
be the most strongly binding GAG with LDL [21]. 
Earlier studies examining the uptake of LDL-proteo- 
glycan complex by macrophages have invariably used 
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CS/DS-PG aggregate that contained proteoglycan 
monomers, hyaluronate, and link protein(s) [13-15]. The 
presence of chondroitin sulfate (CS) and dermatan sulfate 
(DS) isomers in these preparations suggests that the aggre- 
gate probably contains versican and biglycan. Whether 
complexing of LDL with versican (CS-PG) monomer alone 
could alter the metabolism of lipoprotein in macrophages 
remains to be clarified. Also, variations in the nature of 
monomers within the polydisperse CS-PG could influence 
LDL binding affinity and modulate uptake of complex by 
macrophages. 
The objective of the present study was to isolate and 
characterize CS-PG monomers that bind LDL with varying 
affinity, and to determine the ability of these variants to 
modulate LDL metabolism in macrophages. Results show 
that CS-PG monomer, like CS/DS-PG aggregate, is 
equally effective in stimulating LDL uptake and the resul- 
tant cholesteryl ester synthesis in macrophages, the extent 
of which is related to the LDL binding affinity of the 
proteoglycan variant. 
M (200 ml)) at a flow rate of 1.6 ml/min. The eluted 
fractions were analyzed for uronate. 
The fractions under the main uronate peak were pooled, 
dialyzed against 5% (w/v)  calcium acetate/0.5 M acetic 
acid (pH 5.0) at 4°C, and proteoglycans fractionated by a 
sequential ethanol precipitation method of Kapoor et al. 
[24]. The proteoglycan fraction precipitated by 50% ethanol 
(v/v)  was used in the study. 
2.3. Proteoglycan aggregate 
Proteoglycan aggregate preparation from bovine aorta 
was available from previous tudies. In this case, the tissue 
extraction and CsC1 isopycnic centrifugation were per- 
formed under associative condition using 0.5 M Gdn-HCI 
[13]. The bottom two-fifths of the gradient represented 
proteoglycan aggregate. The aggregate contained 18% 
hyaluronate, 19% DS, and 63% CS. 
2.4. Preparation of LDL and lipoprotein-deficient serum 
2. Materials and methods 
2.1. Materials 
The intima-media from bovine thoracic aortas was dis- 
sected, cut into small pieces, and the tissue extracted with 
acetone at 4°C to remove the fat. J774A1 macrophages 
were obtained from American Type Culture Collection 
(Rockville, MD). Unless specified, chemicals, reagents, 
buffer substances, tissue culture medium and supplies, and 
solvents used in this work were obtained from sources 
previously reported [13,21]. 
2.2. Isolation of  proteoglycan monomers 
The dry-defatted intima-media tissue (18.5 g) was ex- 
tracted with 15 vol. of 4.0 M Gdn-HC1 in 0.05 M sodium 
acetate buffer (pH 5.8) containing proteinase inhibitors 
(100 mM e-amino-n-caproic a id, 5 mM N-ethylmalei- 
mide, 5 mM benzamidine-HC1, l0 mM EDTA, 1 mM 
phenylmethylsulfonyl fluoride, and 1 mM iodoacetamide) 
at 4°C for 48 h. The extract was subjected to CsC1 
isopycnic entrifugation at a loading density of 1.4 g/ml, 
40000 rpm, and 8°C for 20 h in a Beckman L2-75B 
centrifuge using a type VTi50 rotor [22]. 
The bottom 2/5  of the gradient, representing most of 
the total uronate of the extract, was dialyzed at 4°C against 
7 M urea in 0.05 M sodium acetate buffer (pH 5.2) 
containing 0.05 M NaCI, 0.05 M LiC1, 0.2% (w/v)  
CHAPS, and the above proteinase inhibitors. The dialyzed 
material was applied to a Sepharose Q anion-exchange 
column (3 x 9 cm) equilibrated with the same urea con- 
taining buffer [23]. Proteoglycans were eluted with two 
linear NaC1 gradients (0.05-1.1 M (200 ml) and 1.1-3.5 
Human LDL (d 1.02-1.05 g/ml) and lipoprotein-defi- 
cient serum (d > 1.215 g/ml) were isolated from pooled 
sera by sequential ultracentrifugation [25]. These prepara- 
tions were dialyzed exhaustively against phosphate- 
buffered saline containing 0.01% EDTA and 10 /xM buty- 
lated hydroxytoluene (BHT), pH 7.4. 
LDL was radio-iodinated with carrier free sodium 
[~25I]iodide according to a modified procedure of McFar- 
lane [26], and sterilized by membrane filtration before use. 
2.5. Gel filtration 
Gel filtration of proteoglycans was performed on a 
Sepharose CL-2B column (0.9 X 60 cm) equilibrated with 
0.05 M sodium acetate buffer (pH 5.8) containing 7 M 
urea, 0.3 M NaC1, and 0.2% CHAPS at a flow rate of 0.1 
ml/min. The column was calibrated with blue dextran for 
void volume, and 5,5'-dithiobis-(2-nitrobenzoic ac d) for 
total volume. The effluent fractions were analyzed for 
uronate. 
2.6. LDL-affinity chromatography 
Proteoglycan monomers was further fractionated by 
LDL-Affi-Gel 10 affinity chromatography as described 
previously [27]. The lipoprotein was coupled to Affi-Gel 
10 (Bio-Rad) using 5 mg LDL protein/ml gel. Proteogly- 
can (500 /zg uronate) was incubated with 20 ml affinity 
gel (5 mg LDL protein/ml) in an equilibrating buffer (10 
mM Tris/10 mM EDTA/10 /xM BHT, pH 8.0) for 30 
min at room temperature. The bound proteoglycan was 
eluted step-wise at a flow rate of 20 ml /h  with 3.5-times 
the gel volume of the equilibrating buffer containing 0.10 
M, 0.25 M, and 1.0 M NaC1. Effluent fractions were 
analyzed for uronate, dialyzed against distilled water, fil- 
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tered through a 0.45 /zm filter, and concentrated under 
vacuum. 
2. 7. Isolation of GAG 
170 kDa were cut from the transfer membrane. These 
membrane strips were directly incubated with 0.1 M NaOH 
or distilled water for 18 h at 26°C, and then hydrolyzed by 
6 M HC1 for 24 h prior to amino acid analysis. 
GAG were isolated from proteoglycan preparations by 
/3-elimination using 0.05 M NaOH and 1.0 M NaBH 4 for 
18 h at 45°C. Samples were deproteinized by passing 
through a Dowex 50 W-X2 (H +) column. 
2.8. Electrophoresis of proteoglycan 
Electrophoresis of proteoglycan was performed in com- 
posite agarose (0.6%)-polyacrylamide (1.8%) gel using 10 
mM Tris-acetate/0.25 mM sodium sulfate buffer (pH 6.8) 
[28]. Prior to electrophoresis, samples were reduced with 
fl-mercaptoethanol. Proteoglycan bands were detected by 
toluidine blue stain. 
2.9. Determination of GAG molecular mass 
The molecular mass of GAG was determined by poly- 
acrylamide gel electrophoresis u ing 6.0% gel and 0.1 M 
Na 3 PO4/0.1 M Na z HPO4/0.125 M HCOONa buffer (pH 
11.5) [29]. Chondroitin sulfate (M r 40000), heparin (M r 
18200), and dextran sulfate (M r 15000) were used as 
standards. GAG were localized in the gel by toluidine 
blue. 
2.10. Determination of core protein molecular mass 
Core protein was obtained by digestion of the proteo- 
glycan with proteinase-free chondroitinase ABC (0.01 
unit//xg proteoglycan protein) in 0.1 M Tris-HCl (pH 
8.0), containing 0.03 M sodium acetate at 37°C for 5 h. 
Core protein in the chondroitinase digest of the proteo- 
glycan was reduced with /3-mercaptoethanol and subjected 
to discontinuous polyacrylamide slab gel electrophoresis 
(6.5% running gel; 3.0% stacking gel) in 0.1 M Tris- 
HCI/0.1 M Tricine/0.1% SDS (pH 8.25) as cathode 
buffer and 0.2 M Tris-HC1 (pH 8.9) as anode buffer [30]. 
Following electrophoresis, proteins on the gel were elec- 
troblotted on Immobilon-P membrane (Millipore, Bedford, 
MA), and the protein bands localized by Sulforhodamine B 
stain (Aldrich Chemicals, Milwaukee, WI). The following 
prestained proteins (Bio-Rad) were used as molecular mass 
standards: myosin (M r 205000), /3-galactosidase (M r 
116 500), bovine serum albumin (M r 80 000), and ovalbu- 
min (M r 49500). 
2.11. Amino acid composition of core protein 
Core protein separated from chondroitinase digest by 
electrophoresis was analyzed for amino acids (before and 
after /3-elimination) using a Beckman 7300 amino acid 
analyzer. Briefly, the core protein bands corresponding to
2.12. Cell culture studies 
J774A1 macrophages were cultured under conditions 
previously described [13]. Cells (-- 106) were incubated at 
37°C in 1 ml Dulbecco's modified Eagle's medium 
(DMEM) containing 10% heat inactivated fetal bovine 
serum and penicillin (100 units/ml)/streptomycin (100 
/xg/ml) in plastic petri dishes for 24 h. Cells were not 
preincubated with lipoprotein-deficient serum in order to 
prevent he up-regulation of LDL-receptor expression. 
Degradation, cell association, and cholesterol esterifica- 
tion assays of the test ligands (50/xg LDL cholesterol/ml) 
were performed in DMEM containing 10% fetal bovine 
serum. In addition, cells were incubated with [~25I]LDL in 
the presence of 10% iipoprotein-deficient serum, in order 
to evaluate the LDL-receptor activity. In all experiments, 
cells were incubated in triplicate at 37°C for 16 h. 
Lysosomal degradation of 125I-labeled ligands was de- 
termined by assaying the trichloroacetic acid-soluble non- 
iodide radioactivity in the medium. Corrections were made 
for small amounts of acid-soluble ~25I-labeled material 
present in control incubations without cells. 
To assay cell-associated ligand, cells were washed with 
buffer (0.15 M NaC1/0.05% Tris, pH 7.4) containing 2
mg/ml albumin and sedimented through fetal bovine serum 
by centrifugation as described previously [31]. The cell 
pellet was counted for radioactivity and then dissolved in 
0.2 M NaOH for protein assay. 
Cellular cholesterol esterification was determined by 
measuring the incorporation of [~C]oleate (ICN Biochemi- 
cals, Costa Mesa, CA) into cholesteryl [~4C]oleate [13]. 
Cells were incubated with 0.2 mM [~4C]oleate-albumin in 
the presence of unlabeled test ligand, and then the cellular 
lipid was extracted with hexane/isopropanol (3:2 v/v). 
The cholesteryl [ ~4C]oleate was isolated by thin-layer chro- 
matography in a developing solvent of heptane/diethyl 
ether/acetic acid (20:30:1 v/v), and counted for radioac- 
tivity. The solvent-extracted cell monolayer was dissolved 
in 02 M NaOH for protein assay. 
2.13. LDL-proteoglycan complex 
Complex of unlabeled LDL or [125I]LDL (100 /zg 
protein/ml) and proteoglycan preparations (5 /zg 
uronate/ml) were prepared in 1 mM Tris buffer (pH 7.4) 
and 30 mM CaCI z as described previously [3]. The insolu- 
ble complex was solubilized in culture medium, and fil- 
tered through a 0.45 /xm filter. The lipoprotein content of 
the complex was measured in terms of cholesterol, and 
aliquots were added to monolayer cultures. 
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2.14. Other procedures 
Uronate was determined by the method of Blu- 
menkrantz and Asboe-Hansen [32]. Hexosamine was deter- 
mined by the method of Boas [33], omitting the use of 
resin after the sample had been hydrolyzed with 4.0 M 
HC1 for 16 h. Total sulfate was determined by the method 
of Terho and Hartiala [34]. Protein was determined by 
Hartree's modification of the Lowry method [35]. Lipopro- 
tein cholesterol was measured by commercial enzymatic 
reagent kit (Autoflo cholesterol 236691, Boehringer-Man- 
nheim Diagnostics, Houston, TX). Distribution of the iso- 
meric chondroitin sulfate in the proteoglycan preparations 
was determined by analyzing the unsaturated disaccharides 
generated from digestion of the sample with chondroiti- 
nases (ABC and AC lyases), using an HPLC column 
(Whatman Partisil-10 PAC) and isocratic elution with 
acetonitrile/methanol/0.5 M ammonium formate buffer 
(60:15:25, pH 4.8) in a Perkin-Elmer Series 3 System [36]. 
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Fig. 2. Gel filtration through Sepharose CL-2B of CS-PG obtained by a 
sequential ethanol precipitation procedure. The proteoglycan was eluted 
from the column with acetate buffer (pH 5.8) containing 7 M urea, 0.3 M 
NaC1, and 0.2% CHAPS. The effluent fractions were analyzed for uronate 
to monitor proteoglycan. 
3. Results 
3.1. Isolation and subfractionation of CS-PG 
Proteoglycans were extracted from intima-media tissue 
under dissociative conditions, and the extract subjected to 
CsC1 isopycnic centrifugation to remove extraneous pro- 
teins. The uronate material contained in the bottom two- 
fifths of the gradient, which represented 2.49 mg/g dry- 
defatted tissue, was then chromatographed on Sepharose Q
anion-exchange column. As shown in Fig. 1, three distinct 
uronate-positive peaks were obtained. The major peak 
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Fig. 1. Ion-exchange chromatography on Sepharose Q of proteoglycans 
obtained by dissociative CsCI isopycnic entrifugation. Prior to applica- 
tion, the sample was exchanged in acetate buffer (pH 5.2) containing 7 M 
urea, 0.05 M NaCI, 0.05 M LiCI, 0.2% (w/v)  CHAPS, and proteinase 
inhibitors. Elution of the bound material was performed by using two 
linear NaCI gradients (0.05 M- I . I  M and 1.1-3.5 M NaCI). The effluent 
fractions were analyzed for uronate to monitor proteoglycan. Fractions 
under the third peak were pooled for further fractionation by a sequential 
ethanol precipitation procedure. 
eluting at 1.2 M NaC1 concentration, which represented 
88% of the total uronate material, contained CS/DS-PG. 
The CS/DS-PG preparation was subjected to a sequen- 
tial ethanol precipitation procedure in order to obtain 
CS-PG devoid of DS isomer. The material precipitated at 
50% (v/v) ethanol concentration represented 10.4% of the 
CS/DS-PG, and contained exclusively CS-PG as deter- 
mined by unsaturated disaccharides generated from chon- 
droitin ABC and AC lyases digestion. The CS-PG fraction 
was then chromatographed on Sepharose-2B in the pres- 
ence of 7 M urea. As seen in Fig. 2, the CS-PG resolved 
into a single peak eluting at a K,v of 0.39. 
The CS-PG monomers were further fractionated by 
affinity chromatography on LDL-Affi-Gel 10. In a three- 
step elution procedure, 57%, 34%, and 9% of the bound 
CS-PG monomers were eluted at 0.10 M, 0.25 M, and 1.0 
M NaC1, respectively. Monomers eluted at 0.1 M and 1.0 
M NaC1, representing relatively low and high LDL binding 
affinity variants, were designated CS-PGI and CS-PGII, 
respectively, and used for further studies. 
3.2. Characteristics of CS-PG subfractions 
Polyacrylamide gel electrophoresis of proteoglycans 
(CS-PGI and CS-PGII) and their constituent GAG chains 
and core protein showed the presence of a single band in 
each case (Fig. 3). While the mobility of core protein of 
CS-PGI and CS-PGII remained the same, CS-PGI and its 
constituent GAG chains migrated relatively fast, reflecting 
their molecular size (discussed below). 
Analyses of protein and GAG moieties of CS-PGI and 
CS-PGII are given in Table 1. The core protein of both 
proteoglycan variants had an apparent molecular mass of 
1.7 • 105. The amino acid composition revealed high levels 
of glutamic acid, glycine, and aspartic acid. After /3- 
elimination, 23.8% and 31.3% of serine residues were lost 
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Fig. 3. Electrophoretograms of intact CS-PGI (1) and CS-PGII (2), and 
their constituent GAG chains and core protein. Electrophoresis of intact 
proteoglycan was performed in agarose (0.5%)-polyacrylamide (1.8%) 
gel using 10 mM Tris-acetate/0.25 mM sodium sulfate buffer (pH 6.8), 
and stained with toluidine blue. GAG obtained by /3-elimination were 
electrophoresed in 6.0% polyacrylamide g l using 0.1 M Na3PO 4/0.1 M 
Na2HPO 4/0.125 M HCOONa buffer (pH 11.5), and localized by Tolui- 
dine blue stain. The core protein obtained by chondroitinase ABC diges- 
tion was reduced with fl-mercaptoethanol and subjected to discontinuous 
SDS-polyacrylamide gel electrophoresis in 0.1 M Tris-HCl/0.1 M 
Tricine/0.1% SDS (pH 8.25) as cathode buffer and 0.2 M Tris-HC1 (pH 
8.9) as anode buffer. Following electrophoresis, the protein was elec- 
troblotted on Immobilon-P membrane and stained by Sulforhodamine B.
from the core protein of CS-PGI and CS-PGII, respec- 
tively. No such loss occurred in threonine residues. 
Based upon the assumption that all serine residues were 
substituted only with GAG, it was estimated that CS-PGII 
contained more GAG chains than CS-PGI (30 vs. 25 
chains). In addition, the average molecular mass of GAG 
of CS-PGII was relatively higher than that of CS-PGI 
(4.2 • 104 vs. 3.8 • 104). The composition of disaccharides 
following hydrolysis of GAG by chondroitinase AC and 
ABC lyases revealed that both CS-PGI and CS-PGII were 
devoid of DS, with the latter containing relatively higher 
proportion of chondroitin 6-sulfate to chondroitin 4-sulfate 
(65:35 vs. 52:48). No disulfated disaccharides were de- 
tected in either proteoglycan variants. Sulfate-to-hexosa- 
mine molar ratio measured approximately one in both 
proteoglycan variants. Based upon core protein and GAG 
data, the molecular masses of CS-PGI and CS-PGII were 
estimated to be 1.12 • 10 6 and 1.43 • 10 6, respectively. 
3.3. Effect on LDL metabolism by macrophages 
Since macrophages from different sources express LDL 
receptor to varying degrees [37], J774A1 macrophages 
were incubated with [125I]LDL (50/xg cholesterol/ml) for 
16 h in the presence of either 10% lipoprotein- deficient 
serum or fetal bovine serum to determine the LDL receptor 
activity under study conditions. The absence of lipopro- 
teins in the medium resulted in, based on per mg cell 
protein, 5.2 _+ 0.8 /zg degradation and 4.8 + 0.6 /xg cell 
association of [125I]LDL, and 10.8 + 1.5 nmol cholesteryl 
oleate formation in macrophages. Corresponding values in 
the presence of lipoprotein in the medium were 1.2 _ 0.2 
/xg, 0.7 + 0.1 /~g, and 3.7 + 0.9 nmol, demonstrating a 
marked down-regulation of LDL receptor activity as ex- 
pected. Therefore, subsequent experiments were performed 
in the presence of 10% fetal bovine serum. 
The effect of interaction of CS-PG variants, CS-PGI 
and CS-PGII, with LDL on the metabolism of lipoprotein 
in macrophage was then studied. For comparison, complex 
Table 1 
Analysis of CS-PGI and CS-PGII fractionated by LDL-affinity chro- 
matography 
Component CS-PGI CS-PGII 
Protein core 
Apparent M~ 1.7- 105 1.7. l05 
Amino acid composition a 
(residues/1000 residues) 
Aspartic acid l 12 115 
Threonine 67 66 
Serine 63 (48) b 64 (44) b 
Glutamic acid 138 136 
Proline 44 42 
Glycine 121 119 
A|anine 81 81 
Cystine - - 
Valine 73 71 
Methionine 7 7 
Isoleucine 46 44 
Leucine 74 76 
Tyrosine 22 25 
Phenylalanine 34 33 
Lysine 63 65 
Histidine 24 24 
Arginine 31 30 
Glycosaminoglycan chain 
Apparent M r 3.8. l04 4.2.104 
Number of chains/core protein ~ 25 30 
Sulfate (mol/mol hexosamine) 1.01 0.97 
Disaccharide composition (%) 
GIcUA-GalNAc6-S 52 65 
GIcUA-GalNAc4-S 48 35 
IdUA-GalNAc4-S 0 0 
GIcUA, glucuronic acid; IdUA, iduronic acid; GalNAc4-S, N-acetyl 
galactosamine 4-sulfate; GalNAe6-S, N-acetylgalactosamine 6-sulfate. 
a No corrections were made for losses during hydrolysis. 
b After/3-elimination. 
c Based on the number of glycosylated serine. 
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Fig. 4. The effect of interaction fCS-PGI and CS-PGII with LDL on the 
metabolism of lipoprotein macrophages. Complex of LDL and proteo- 
glycan aggregate (CS/DS-PGA) was included for comparison. Cells 
were incubated in DMEM containing 10% fetal bovine serum at 37°C. 
After 24 h fresh medium (same as above) containing test ligand (50 txg 
LDL cholesterol/ml) was added. [1251]LDL degradation a d cell-associ- 
ated radioactivity were determined after 16 h. For the cholesterol esterifi- 
cation assay, cells were incubated with 0.2 mM [14C]oleate-albumin in 
the presence ofunlabeled test ligand (50 /.~g LDL cholesterol/ml) for16 
h and the cellular content of cholesteryl [t4C]oleate was determined. Each 
value represents the mean +_ S.E. of triplicate cultures. 
of LDL and CS/DS PG aggregate was studied under 
similar conditions. Results on degradation, cell association, 
and cholesterol esterification are shown in Fig. 4, after a 
16 h incubation of the ligand (50 ~g LDL cholesterol/ml) 
with macrophages. When compared to complex of 
[125I]LDL and CS-PGI, complex of [125I]LDL and CS-PGII 
produced consistent increase in degradation by 
macrophages (10.3-fold vs. 8.4-fold over [125I]LDL alone). 
At the same time, macrophages accumulated more cell 
associated radioactivity from [lzSI]LDL-CS-PGII complex 
than from [125I]LDL-CS-PGI complex (16.3-fold vs. 
10.2-fold over [125I]LDL alone). In addition, complex of 
LDL and CS-PGII increased the stimulation of cholesteryl 
ester synthesis in macrophages, when compared to com- 
plex of LDL and CS-PGI (8.4-fold vs. 6.4-fold over native 
LDL). When complexed with LDL, both CS-PGII and 
CS/DS-PG aggregate produced similar effects on the 
above-mentioned cellular activities. 
4. Discussion 
In general, proteoglycan of the same type, like versican, 
displays heterogeneity in terms of hydrodynamic size, 
charge density, and chemical characteristics of the con- 
stituent GAG. While the density gradient ultracentrifuga- 
tion procedure as described by Oegema et al. [22] separates 
arterial tissue CS/DS-PG according to the number of 
GAG chains per core protein, the ethanol precipitation 
procedure of Kapoor et al. [24] separates these proteogly- 
cans according to the iduronate and glucuronate content of 
the constituent GAG chains. In the present study, combina- 
tion of these two procedures resulted in isolation of pure 
CS-PG monomers (devoid of DS isomer) eluting as a 
single peak (Ka~ =0.39) upon gel filtration through 
Sepharose CL-2B. 
The CS-PG monomers were further fractionated by 
LDL-affinity chromatography. Although several fractions 
of CS-PG could have been obtained by varying the NaC1 
concentration of the eluting buffer, only two fractions, 
CS-PGI and CS-PGII, with relatively low and high LDL- 
binding affinity were used for comparative purpose. It 
should be noted that both CS-PGI and CS-PGII are vari- 
ants of the arterial tissue versican which is present as a 
polydisperse macromolecule in the vasculature. 
The LDL binding potential of CS-PG variants appears 
to be primarily related to GAG moiety. The core protein of 
both CS-PG variants displayed identical molecular size 
(M r 1.7 • 105), consistent with those reported for the arte- 
rial tissue versican [7,38,39]. However, CS-PGII contained 
more GAG chains (30 vs. 25) with relatively higher molec- 
ular mass (4.2- 10 4 VS. 3.8 • 10 4) than CS-PGI. The above 
characteristics onfer on CS-PGII a relatively high hydro- 
dynamic size and charge density that are critical to LDL 
binding [7,18-21,40], although the degree of sulfation 
remained the same between these variants. 
It is now well established that the interaction between 
LDL and arterial tissue CS/DS-PG aggregate results in 
altered lipoprotein metabolism leading to cholesteryl ester 
accumulation i  macrophages [13-16]. The present study 
demonstrates that a proteoglycan monomer of versican 
type alone can stimulate LDL uptake (cell association and 
degradation) and cholesteryl ester synthesis in 
macrophages, the magnitude of which is related to the 
LDL binding affinity of the proteoglycan variant. It is 
noteworthy that although CS-PGII constitutes only a minor 
portion of versican, it is as potent as native CS/DS-PG 
aggregate in altering LDL metabolism in macrophages. 
The occurrence of a potent LDL binding variant within 
versican may be relevant to the process of lipid accumula- 
tion in atherogenesis. Proteoglycan variant with character- 
istics similar to those of CS-PGII may be selectively 
produced in excess during atherogenesis. Increases in hy- 
drodynamic size of CS/DS-PG is noted in both human 
and experimental therosclerosis [39,41]. Experimental in- 
jury to the arterial wall is known to produce CS/DS-PG 
with enhanced affinity for LDL [27,42]. This increased 
affinity was found to be related to increases in hydrody- 
namic size of the proteoglycan as a consequence of elonga- 
tion of the cognate GAG chains [27]. Further, at the 
cellular level, proliferating smooth muscle cells exposed to 
growth factors produce versican with longer GAG chains 
and higher proportion of chondroitin 6-sulfate isomer 
[43,44], resulting in enhanced LDL binding affinity [44]. 
The consistency of these findings with the current observa- 
tions suggest that variations within a proteoglycan type can 
S.R. Srinivasan et al. / Biochimica et Biophysica Acta 1272 (1995) 61-67 67 
influence LDL binding affinity and modulate lipid accu- 
mulation in atherogenesis. 
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